Improving quality of life through innovations in urology.
Get news and information for
healthcare professionals
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences Appoints James Robinson as...
on March 23, 2020
Mr. Robinson will assume the role of President and CEO and continue as a Urovant Board Member Mr. […]
Read Latest Post -
Urovant Sciences Announces U.S. FDA...
on March 5, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV) today […]
Read Latest Post -
Urovant Sciences Announces Publication of...
on March 2, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV) […]
Read Latest Post
View more
Copyright 2018 © All Rights Reserved